ClinicalTrials.gg
CompletedNCT05432232CAINUpdated Sep 11, 2026Results posted

The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy

An interventional study of HistoSonics Investigational System in Renal Cancer, Tumor, Solid and Kidney Cancer, sponsored by HistoSonics, Inc.. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by HistoSonics, Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 66 studies in Kidney Neoplasms with a site in United Kingdom — 12 open to participants now, 15 under way, 2 of them phase 3. Kidney Neoplasms · United Kingdom.

Enrollment
47th of 52
20 · median 126
Started
2023
with 4 others
No phase
10 of 66
4 open now
Registered
55th of 66
by date

Among the 66 studies in Kidney Neoplasms with a site in United Kingdom, this one is the 47th largest by enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2023, is one of 10 with no phase, and was the 55th registered.

Kidney Neoplasms

969 studies on the registry are indexed under Kidney Neoplasms; 208 are open to participants now.

Browse Kidney Neoplasms studies →

Open to participants now

12 of the 66 studies in Kidney Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 171 Kidney Neoplasms studies recruiting now, 131 (77%) set no upper age limit and 15 (9%) stop at 75 or younger; 20 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Kidney Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose of this trial is to evaluate the technical success and safety profile of the HistoSonics Investigational System for the treatment of primary solid renal tumors.

Read the detailed description

This trial is a prospective, multi-center, single-arm pilot trial designed to evaluate the effectiveness and safety profile of the HistoSonics Investigational System in treating primary solid renal tumors. Following histotripsy treatment of the solid renal tumor, subjects will undergo imaging ≤36 hours post-index procedure to determine technical success. Additionally, subjects will be followed 180 days (6 months) post-index procedure, with evaluations at the 14-day, 30-day, 90-day, and 180-day time points to establish the efficacy and safety profile of the HistoSonics Investigational System.

03

Conditions studied

  • Renal Cancer
  • Tumor, Solid
  • Kidney Cancer
  • Tumor
  • Tumor, Benign
  • Kidney Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is ≥18 years of age.
  2. Subject has signed the Ethics Committee (EC) approved trial Form (ICF) prior to any trial related tests/procedures and is willing to comply with trial procedures and required follow-up assessments.
  3. Subject is diagnosed with a non- solid renal mass ≤3cm confirmed via CT or MRI ≤ 30 days prior to the index procedure date.
  4. Subject can tolerate general anesthesia.
  5. Subject has an Performance Status (ECOG PS) grade 0-2 at baseline screening.
  6. Subject meets all the following functional criteria at ≤14 days prior to the planned index procedure date:

    • White Blood Cell (WBC) ≥3,000/mm3
    • (ANC) ≥1,200/mm3
    • (Hgb) ≥9 g/dL
    • count ≥100,000/mm3 (≥100 10*9/L)
    • White Blood Cell (WBC) ≤40 cells/µL via urinalysis
    • Albumin ≤300,000 mg/L via urinalysis
  7. Subject has an ≥45mL/min, ≤14 days prior to the planned index procedure date.
  8. (INR) score of \<1.5:

    • If on anticoagulants, other than aspirin or non-steroidal anti-inflammatory drugs, assessment must be performed on the day of the procedure; OR
    • If only on aspirin or non-steroidal anti-inflammatory drugs, assessment must be performed ≤14 days prior to the planned index procedure date; OR
    • If not on anticoagulants, assessment must be performed ≤14 days prior to the planned index procedure date
  9. is required to determine the type of tumor and must be performed ≥14 days prior to the planned index procedure date.
  10. The tumor selected for histotripsy treatment must be ≤3cm in longest diameter.
  11. Subject has an adequate acoustic window to visualize targeted tumor using the HistoSonics System.
  12. Subject will undergo histotripsy treatment of only one (1) tumor during the index procedure, regardless of how many tumors the subject has.

Exclusion criteria

Exclusion Criteria:

  1. Subject is pregnant or planning to become pregnant or nursing (lactating) during the trial period.
  2. Subject is enrolled and being actively treated in another pharmaceutical or device trial ≤30 days prior to planned index procedure date.
  3. Subject is undergoing active chemotherapy for any cancer ≤14 days prior to planned index procedure date.
  4. Subject is undergoing active immunotherapy ≤40 days prior to planned index procedure date.
  5. In the Investigator's opinion, the subject has co-morbid disease(s) or condition(s) that would cause undue risk and preclude safe use of the HistoSonics Investigational System.
  6. Subject is on dialysis or being considered for dialysis.
  7. Subject has not recovered to (CTCAE) grade 2 or better from any adverse effects (except alopecia and neuropathy) related to previous anti-cancer therapy.
  8. Subject has an uncorrectable coagulopathy other than that induced by aspirin or non-steroidal anti-inflammatory drugs.
  9. Subject has a planned cancer treatment (e.g., nephrectomy, chemotherapy, immunotherapy etc.) prior to completion of the 30-day follow-up visit.
  10. Subject has had previous treatments with chemotherapy, radiotherapy, or both that have not been discontinued ≥14 days prior to the planned index procedure date and have not recovered (CTCAE grade 2 or better) from related toxicity (exclusive of alopecia and neuropathy).
  11. Subject has previous treatment with immunotherapies that has not been discontinued ≥40-days prior to the planned index procedure date and has not recovered from related toxicity (CTCAE grade 2 or better).
  12. Subject has a less than one (\< 1) year.
  13. In the investigator's opinion, histotripsy is not a treatment option for the subject.
  14. Subject has a concurrent condition that could jeopardize the safety of the subject or compliance with the protocol.
  15. Subjects' targeted tumor has had prior locoregional therapy (e.g., ablation, embolization, radiation).
  16. Subjects' tumor is not treatable by the HistoSonics Investigational System's working ranges (refer to User Guide).
  17. In the physician's opinion, the anticipated risk of intervention outweighs the potential benefits of the intervention.
  18. Subject has acute renal failure.
  19. Subject has a genetic predisposition to kidney cancer such as:

    • Von Hippel Lindau (VHL)
    • Hereditary Papillary Renal Carcinoma (HPRC)
    • Birt-Hogg-Dubé Syndrome (BHD)
    • Tuberous Sclerosis Complex (TSC)
    • Hereditary Leiomyomata's Renal Cell Carcinoma (HLRCC)
    • Reed's Syndrome
    • Succinate Dehydrogenase B Deficiency (SDHB)
    • BRCA 1 associated protein -1 (BAP1) Renal Cell Carcinoma
    • MITF predisposed Renal Cell Carcinoma
  20. Tumor is an angiomyolipoma.
  21. Subject has a known sensitivity to contrast media and cannot be adequately pre-medicated.
  22. The targeted tumor is not clearly visible with diagnostic ultrasound and either magnetic resonance imaging (MRI) or computerized tomography (CT).
  23. Targeted tumor with adequate margin overlaps the renal pelvis, main renal vessel, ureter, or other vital structure.
  24. Targeted tumor with adequate margin overlaps a non-targeted tumor visible via imaging.
  25. The treatment of the tumor will not allow for an adequate margin as determined by the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    HistoSonics Investigational System

    Device: HistoSonics Investigational System

Interventions

  • DeviceHistoSonics Investigational System

    The HistoSonics Investigational System is intended for the non-invasive destruction of kidney tissue using histotripsy, a non-thermal mechanical process of focused ultrasound.

    Also known as: Histotripsy

06

What researchers measure

Primary outcomes

  1. Primary Effectiveness: Technical Success

    Technical success, defined as complete coverage of the tumor as determined ≤36 hours post-index procedure by magnetic resonance imaging (MRI) or computerized tomography (CT). \[Core Lab Adjudicated\]

    Time frame: Up to 36 hours after the index procedure

  2. Primary Safety: Freedom From Index Procedure Related Major Complications

    Freedom from index procedure related major complications, defined by Clavien-Dindo Classification Grade 3 or higher up to 30 days after the last histotripsy procedure. \[Clinical Events Committee Adjudicated\]

    Time frame: 30 days Post-Index Procedure

Secondary outcomes

  1. Technique Efficacy (Primary)

    The secondary endpoint of Technique Efficacy (Primary) was defined as the percentage of targeted tumors successfully eradicated post-index procedure assessed via MRI or CT at 90-days post-index procedure without repeat Histotripsy \[Core Lab Adjudicated\]

    Time frame: 90 days Post-Index Procedure

  2. Technique Efficacy (Secondary)

    The secondary endpoint of Technique Efficacy (Secondary) was defined as the percentage of targeted tumors successfully eradicated post-index procedure assessed via MRI or CT at 90-days post-index procedure either without or with repeat Histotripsy \[Core Lab Adjudicated\]

    Time frame: 90 days Post-Index Procedure

07

Results

Posted Dec 2, 2025

Participant flow

The trial enrolled participants between March 2023 and November 2024 at one (1) UK site. All eligible subjects who provided informed consent were considered enrolled. Only subjects enrolled and treated with the HistoSonics Investigational System were assessed for the primary and secondary endpoints.

Participant Screening
Participant flow — Participant Screening
MilestoneHistoSonics Investigational System
Started20
Screen failures9
Completed11
Not completed9
Treatment to 180-Day Follow-up
Participant flow — Treatment to 180-Day Follow-up
MilestoneHistoSonics Investigational System
Started11
Completed11
Not completed0

Outcome measures

PrimaryPrimary Effectiveness: Technical Success

Technical success, defined as complete coverage of the tumor as determined ≤36 hours post-index procedure by magnetic resonance imaging (MRI) or computerized tomography (CT). \[Core Lab Adjudicated\]

Time frame:
Up to 36 hours after the index procedure
Reported as:
Number · percentage of tumors
Primary Effectiveness: Technical Success
percentage of tumorsHistoSonics Investigational System
Primary Effectiveness: Technical Success100.0 (71.5 to 100.0)
PrimaryPrimary Safety: Freedom From Index Procedure Related Major Complications

Freedom from index procedure related major complications, defined by Clavien-Dindo Classification Grade 3 or higher up to 30 days after the last histotripsy procedure. \[Clinical Events Committee Adjudicated\]

Time frame:
30 days Post-Index Procedure
Reported as:
Number · percentage of participants
Primary Safety: Freedom From Index Procedure Related Major Complications
percentage of participantsHistoSonics Investigational System
Primary Safety: Freedom From Index Procedure Related Major Complications90.9 (58.7 to 99.8)
SecondaryTechnique Efficacy (Primary)

The secondary endpoint of Technique Efficacy (Primary) was defined as the percentage of targeted tumors successfully eradicated post-index procedure assessed via MRI or CT at 90-days post-index procedure without repeat Histotripsy \[Core Lab Adjudicated\]

Time frame:
90 days Post-Index Procedure
Reported as:
Number · percentage of tumors
Technique Efficacy (Primary)
percentage of tumorsHistoSonics Investigational System
Technique Efficacy (Primary)70.0 (34.8 to 93.3)
SecondaryTechnique Efficacy (Secondary)

The secondary endpoint of Technique Efficacy (Secondary) was defined as the percentage of targeted tumors successfully eradicated post-index procedure assessed via MRI or CT at 90-days post-index procedure either without or with repeat Histotripsy \[Core Lab Adjudicated\]

Time frame:
90 days Post-Index Procedure
Reported as:
Number · percentage of tumors
Technique Efficacy (Secondary)
percentage of tumorsHistoSonics Investigational System
Technique Efficacy (Secondary)70.0 (34.8 to 93.3)

Adverse events

Collected over Histotripsy treatment through 180-day visit. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HistoSonics Investigational System0/11 (0%)5/11 (45.5%)11/11 (100%)
Most frequent serious events
Most frequent serious events
EventHistoSonics Investigational System
Renal neoplasmRenal and urinary disorders2/11
VomitingGastrointestinal disorders1/11
Urinary retention postoperativeInjury, poisoning and procedural complications1/11
EmphysemaRespiratory, thoracic and mediastinal disorders1/11
Obstructive airways disorderRespiratory, thoracic and mediastinal disorders1/11
Abdominal painGastrointestinal disorders1/11
Most frequent other events
Showing 10 of 33
Most frequent other events
EventHistoSonics Investigational System
HaematuriaRenal and urinary disorders10/11
ConstipationGastrointestinal disorders4/11
Back painMusculoskeletal and connective tissue disorders4/11
VomitingGastrointestinal disorders3/11
Influenza like illnessGeneral disorders3/11
Abdominal pain lowerGastrointestinal disorders2/11
PainGeneral disorders2/11
Decreased appetiteGeneral disorders2/11
White blood cell count increasedInvestigations2/11
HeadacheNervous system disorders2/11

Baseline characteristics

Participants treated with histotripsy

Age, Continuous
Age, Continuous(years)HistoSonics Investigational System
Median71.0 (59.0 to 79.0)
Sex: Female, Male
Sex: Female, Male(Participants)HistoSonics Investigational System
Female4
Male7
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HistoSonics Investigational System
Hispanic or Latino0
Not Hispanic or Latino11
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)HistoSonics Investigational System
White10
Other1
08

Study locations

1 site
  • Leeds Teaching Hospitals NHS Trust
    Leeds, LS9 7TF, United Kingdom
09

References and documents

Publications

  • Wah TM, Abdel-Hadi O, Brandon J, Bhambra B, Glencross H, Occidental J, Stones JM, Vasudev N, Bhattarai S, Cartledge J. Early Clinical Histotripsy Treatment of Renal Cell Carcinoma. Cardiovasc Intervent Radiol. 2025 Jun;48(6):883-885. doi: 10.1007/s00270-025-04023-9. Epub 2025 Apr 28. No abstract available. PubMed 40295402 ↗
  • Wah TM, Amaral JF, Laeseke PF. Treatment of Primary Solid Renal Tumours Using Histotripsy: Study Protocol for the CAIN Feasibility Trial. Cardiovasc Intervent Radiol. 2025 Jun;48(6):857-865. doi: 10.1007/s00270-025-04035-5. Epub 2025 Apr 28. PubMed 40295399 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Dec 2024, 21 months.

Results were first posted in Dec 2025, 11 months after primary completion.

Of 97 interventional studies with no phase under Kidney Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 90. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2022
First posted
Jun 27, 2022
StartActual
Mar 23, 2023
Primary completionActual
Dec 28, 2024
CompletionActual
Jun 6, 2025
Results first posted
Dec 2, 2025
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05432232
Lead sponsor
HistoSonics, Inc.
Responsible party
Sponsor
First posted
Jun 27, 2022
Start date
Mar 23, 2023
Primary completion
Dec 28, 2024
Completion
Jun 6, 2025
Results posted
Dec 2, 2025
Last update
Sep 11, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion